NASDAQ:NCNA - NuCana Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$27.75 +0.08 (+0.29 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$27.75
Today's Range$26.9075 - $28.00
52-Week Range$9.32 - $30.41
Volume13,982 shs
Average Volume46,676 shs
Market Capitalization$880.22 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About NuCana (NASDAQ:NCNA)

NuCana logoNuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematological malignancies. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NCNA
CUSIPN/A
Phone44-0-13-1248-3660

Debt

Debt-to-Equity RatioN/A
Current Ratio34.95
Quick Ratio32.30

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.83 per share
Price / Book7.25

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees16
Outstanding Shares31,810,000

NuCana (NASDAQ:NCNA) Frequently Asked Questions

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

What price target have analysts set for NCNA?

4 Wall Street analysts have issued 1-year target prices for NuCana's stock. Their predictions range from $23.00 to $25.00. On average, they anticipate NuCana's stock price to reach $24.00 in the next twelve months. View Analyst Ratings for NuCana.

Who are some of NuCana's key competitors?

Who are NuCana's key executives?

NuCana's management team includes the folowing people:
  • Prof. Christopher B. Wood Ph.D., M.D., FRCS, Chairman & Chief Medical Officer (Age 72)
  • Mr. Hugh S. Griffith, Founder, Chief Exec. Officer and Director (Age 50)
  • Mr. Donald Munoz, CFO & Principal Accounting Officer (Age 49)

When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

When did NuCana's lock-up period expire?

NuCana's lock-up period expired on Tuesday, March 27th. NuCana had issued 6,667,000 shares in its IPO on September 28th. The total size of the offering was $100,005,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Has NuCana been receiving favorable news coverage?

News headlines about NCNA stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuCana earned a media sentiment score of 0.02 on Accern's scale. They also gave news headlines about the company an impact score of 47.43 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are NuCana's major shareholders?

NuCana's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sofinnova Ventures Inc (14.67%), Baillie Gifford & Co. (2.02%), Alps Advisors Inc. (0.13%), Asymmetry Capital Management L.P. (0.13%), Millennium Management LLC (0.04%) and Citadel Advisors LLC (0.04%). View Institutional Ownership Trends for NuCana.

Which institutional investors are selling NuCana stock?

NCNA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Citadel Advisors LLC. View Insider Buying and Selling for NuCana.

Which institutional investors are buying NuCana stock?

NCNA stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Baillie Gifford & Co., Asymmetry Capital Management L.P. and Alps Advisors Inc.. View Insider Buying and Selling for NuCana.

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $27.75.

How big of a company is NuCana?

NuCana has a market capitalization of $880.22 million. The company earns $-29,750,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. NuCana employs 16 workers across the globe.

How can I contact NuCana?

NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-0-13-1248-3660.


MarketBeat Community Rating for NuCana (NCNA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NuCana (NASDAQ:NCNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for NuCana in the last 12 months. Their average twelve-month price target is $24.00, suggesting that the stock has a possible downside of 13.51%. The high price target for NCNA is $25.00 and the low price target for NCNA is $23.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00$24.00$24.00
Price Target Upside: 13.51% downsideN/AN/AN/A

NuCana (NASDAQ:NCNA) Consensus Price Target History

Price Target History for NuCana (NASDAQ:NCNA)

NuCana (NASDAQ:NCNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2018CowenReiterated RatingBuyLowView Rating Details
10/23/2017William BlairInitiated CoverageOutperform ➝ OutperformN/AView Rating Details
10/23/2017CitigroupInitiated CoverageBuy ➝ Buy$23.00N/AView Rating Details
10/23/2017Jefferies GroupInitiated CoverageBuy ➝ Buy$25.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Dividends

NuCana (NASDAQ:NCNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NuCana (NASDAQ NCNA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 46.34%
Insider Trading History for NuCana (NASDAQ:NCNA)
Institutional Ownership by Quarter for NuCana (NASDAQ:NCNA)

NuCana (NASDAQ NCNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

NuCana (NASDAQ NCNA) News Headlines

Source:
DateHeadline
NuCana to Participate in the Jefferies 2018 Global Healthcare ConferenceNuCana to Participate in the Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - May 25 at 4:27 PM
NuCana (NCNA) Receives Buy Rating from CowenNuCana (NCNA) Receives Buy Rating from Cowen
www.americanbankingnews.com - May 24 at 1:27 PM
NuCana Reports First Quarter 2018 Financial ResultsNuCana Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 23 at 4:25 PM
NuCana plc: NuCana Announces Appointment of Cyrille Leperlier to its Board of DirectorsNuCana plc: NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors
www.finanznachrichten.de - May 21 at 9:27 AM
NuCana Announces Appointment of Cyrille Leperlier to its Board of DirectorsNuCana Announces Appointment of Cyrille Leperlier to its Board of Directors
finance.yahoo.com - May 21 at 9:27 AM
 Brokerages Anticipate NuCana (NCNA) to Announce -$0.22 Earnings Per Share Brokerages Anticipate NuCana (NCNA) to Announce -$0.22 Earnings Per Share
www.americanbankingnews.com - May 20 at 11:14 PM
NuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award from Life Sciences ScotlandNuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award from Life Sciences Scotland
finance.yahoo.com - May 17 at 9:53 AM
Zacks: Brokerages Expect NuCana (NCNA) Will Post Earnings of -$0.22 Per ShareZacks: Brokerages Expect NuCana (NCNA) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - May 3 at 6:52 PM
NuCana (NCNA) Stock Rating Upgraded by ValuEngineNuCana (NCNA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 11:37 PM
NuCana (NCNA) Receives Average Recommendation of "Buy" from BrokeragesNuCana (NCNA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 3:34 AM
Zacks: NuCana (NCNA) Given $26.50 Average Target Price by BrokeragesZacks: NuCana (NCNA) Given $26.50 Average Target Price by Brokerages
www.americanbankingnews.com - April 18 at 1:18 AM
NuCana (NCNA) Expected to Announce Earnings of -$0.22 Per ShareNuCana (NCNA) Expected to Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - April 16 at 11:14 AM
NuCana plc Announces Appointment of Adam George to its Board of DirectorsNuCana plc Announces Appointment of Adam George to its Board of Directors
finance.yahoo.com - April 9 at 9:55 AM
NuCana (NCNA) Now Covered by Analysts at CitigroupNuCana (NCNA) Now Covered by Analysts at Citigroup
www.americanbankingnews.com - April 6 at 12:11 PM
NuCana (NCNA) Now Covered by CowenNuCana (NCNA) Now Covered by Cowen
www.americanbankingnews.com - April 6 at 11:11 AM
NuCana (NCNA) Coverage Initiated at Jefferies GroupNuCana (NCNA) Coverage Initiated at Jefferies Group
www.americanbankingnews.com - April 6 at 10:58 AM
Zacks: NuCana (NCNA) Given Consensus Rating of "Strong Buy" by AnalystsZacks: NuCana (NCNA) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 3 at 1:24 PM
-$0.14 Earnings Per Share Expected for NuCana PLC (NCNA) This Quarter-$0.14 Earnings Per Share Expected for NuCana PLC (NCNA) This Quarter
www.americanbankingnews.com - March 30 at 3:12 PM
Zacks Investment Research Lowers NuCana (NCNA) to HoldZacks Investment Research Lowers NuCana (NCNA) to Hold
www.americanbankingnews.com - March 30 at 9:17 AM
NuCana (NCNA) Raised to "Buy" at Zacks Investment ResearchNuCana (NCNA) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 6:22 PM
NuCana (NCNA) Stock Rating Lowered by Zacks Investment ResearchNuCana (NCNA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 28 at 1:32 PM
NuCana Reports Financial Results for the Year Ended December 31, 2017NuCana Reports Financial Results for the Year Ended December 31, 2017
finance.yahoo.com - March 21 at 4:13 PM
NuCana PLCs Lock-Up Period To End  on March 27th (NASDAQ:NCNA)NuCana PLC's Lock-Up Period To End on March 27th (NASDAQ:NCNA)
www.americanbankingnews.com - March 20 at 1:16 AM
Zacks: NuCana PLC (NCNA) Given $26.50 Average Target Price by BrokeragesZacks: NuCana PLC (NCNA) Given $26.50 Average Target Price by Brokerages
www.americanbankingnews.com - March 19 at 3:22 AM
Zacks: Analysts Set $26.50 Price Target for NuCana PLC (NCNA)Zacks: Analysts Set $26.50 Price Target for NuCana PLC (NCNA)
www.americanbankingnews.com - March 14 at 3:26 AM
NuCana PLC (NCNA) Expected to Announce Earnings of -$0.14 Per ShareNuCana PLC (NCNA) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - March 13 at 11:49 AM
Zacks: NuCana PLC (NCNA) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: NuCana PLC (NCNA) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 8 at 9:29 PM
Brokerages Anticipate NuCana PLC (NCNA) to Post ($0.14) Earnings Per ShareBrokerages Anticipate NuCana PLC (NCNA) to Post ($0.14) Earnings Per Share
www.americanbankingnews.com - March 3 at 5:28 AM
NuCana plc to Participate in the Cowen and Company 38th Annual Health Care ConferenceNuCana plc to Participate in the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 2 at 9:31 AM
Zacks: NuCana PLC (NCNA) Given Consensus Rating of "Strong Buy" by AnalystsZacks: NuCana PLC (NCNA) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - February 25 at 3:29 PM
NuCana (NCNA) Upgraded by Zacks Investment Research to HoldNuCana (NCNA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 21 at 6:26 AM
Brokerages Anticipate NuCana PLC (NCNA) to Announce ($0.14) EPSBrokerages Anticipate NuCana PLC (NCNA) to Announce ($0.14) EPS
www.americanbankingnews.com - February 15 at 3:32 PM
Analysts Anticipate NuCana PLC (NCNA) to Post ($0.14) Earnings Per ShareAnalysts Anticipate NuCana PLC (NCNA) to Post ($0.14) Earnings Per Share
www.americanbankingnews.com - January 30 at 1:32 PM
NuCana (NCNA) Cut to "Sell" at Zacks Investment ResearchNuCana (NCNA) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 25 at 6:50 AM
NuCana PLC Forecasted to Earn Q1 2018 Earnings of ($0.12) Per Share (NCNA)NuCana PLC Forecasted to Earn Q1 2018 Earnings of ($0.12) Per Share (NCNA)
www.americanbankingnews.com - January 24 at 9:02 AM
Wired News – NuCana Announced Positive Results from Clinical Data on Acelarin® as Front-Line Treatment of Advanced Biliary Tract Cancer at ASCO GI 2018Wired News – NuCana Announced Positive Results from Clinical Data on Acelarin® as Front-Line Treatment of Advanced Biliary Tract Cancer at ASCO GI 2018
finance.yahoo.com - January 23 at 8:28 AM
Here’s What’s Moving NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMKTS:PHMMF)Here’s What’s Moving NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMKTS:PHMMF)
finance.yahoo.com - January 22 at 5:42 PM
NuCana (NCNA) Upgraded to Buy at Zacks Investment ResearchNuCana (NCNA) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - January 21 at 8:58 PM
NuCana PLC (NCNA) Expected to Post Earnings of -$0.12 Per ShareNuCana PLC (NCNA) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - January 21 at 3:26 PM
NuCana (NCNA) Reports Promising Clinical Data at ASCO GI on NUC-1031 as Front-Line Treatment of Advanced Biliary Tract CancerNuCana (NCNA) Reports Promising Clinical Data at ASCO GI on NUC-1031 as Front-Line Treatment of Advanced Biliary Tract Cancer
www.streetinsider.com - January 20 at 8:51 AM
NuCana Planning to Initiate a Phase 3 Study of Acelarin in Front-Line Advanced Biliary Tract CancerNuCana Planning to Initiate a Phase 3 Study of Acelarin in Front-Line Advanced Biliary Tract Cancer
www.nasdaq.com - January 20 at 8:51 AM
 NuCana PLC (NCNA) Receives Consensus Recommendation of "Strong Buy" from Brokerages NuCana PLC (NCNA) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 28 at 1:38 AM
NuCana (NCNA) Upgraded to "Buy" at Zacks Investment ResearchNuCana (NCNA) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - December 26 at 6:04 AM
Analysts Offer Predictions for NuCana PLCs FY2017 Earnings (NCNA)Analysts Offer Predictions for NuCana PLC's FY2017 Earnings (NCNA)
www.americanbankingnews.com - December 25 at 1:58 AM
 Analysts Set $24.00 Target Price for NuCana PLC Sponsored ADR (NCNA) Analysts Set $24.00 Target Price for NuCana PLC Sponsored ADR (NCNA)
www.americanbankingnews.com - December 13 at 7:54 AM
Reviewing NuCana (NCNA) and Its CompetitorsReviewing NuCana (NCNA) and Its Competitors
www.americanbankingnews.com - December 1 at 11:36 PM
Zacks: NuCana PLC Sponsored ADR (NCNA) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: NuCana PLC Sponsored ADR (NCNA) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 27 at 1:14 AM
NuCana plc to Participate in the Evercore ISI Biopharma Catalyst / Deep Dive ConferenceNuCana plc to Participate in the Evercore ISI Biopharma Catalyst / Deep Dive Conference
finance.yahoo.com - November 20 at 8:07 AM
NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian CancerNuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer
finance.yahoo.com - November 18 at 6:56 AM
Zacks: NuCana PLC Sponsored ADR (NCNA) Given $24.00 Average Price Target by BrokeragesZacks: NuCana PLC Sponsored ADR (NCNA) Given $24.00 Average Price Target by Brokerages
www.americanbankingnews.com - November 12 at 3:56 PM

SEC Filings

NuCana (NASDAQ:NCNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NuCana (NASDAQ:NCNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NuCana (NASDAQ NCNA) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.